In fact, an in-vivo mouse study on three spontaneous mouse cancer models for breast cancer, pancreatic cancer and glioblastoma found that VEGF inhibition when combined with anti-PDL1 therapy was successful only when it induced HEV neogenesis in the breast and pancreatic cancer model but not in the glioblastoma model. This evidence concerns the gene CD274 and breast carcinoma.